Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Am J Gastroenterol. 2019 Jun;114(6):984–994. doi: 10.14309/ajg.0000000000000228

Table 5.

Initial treatment of EGID by diagnosis sorted by type of medication and diet modification.

EG N = 142 (n, %) EGE N = 123 (n, %) EC N = 108 (n, %) P-value
Medications
PPI 86 (61%) 74 (60%) 32 (30%) < 0.001
Topical corticosteroids 33 (23%) 24 (20%) 11 (10%) 0.008
Systemic corticosteroids 28 (20%) 30 (24%) 20 (19%) 0.34
Crushed enteric coated budesonide 18 (13%) 12 (10%) 21 (19%) 0.016
5-ASA 1 (1%) 4 (3%) 27 (25%) < 0.001
Immune modulating drug 5 (4%) 4 (3%) 8 (7%) 0.34
Mast cell agent 1 (1%) 2 (2%) 4 (4%) 0.65
Monoclonal antibody 2 (1%) 4 (3%) 1 (1%) 0.15
Diet Modification
Six-food elimination 5 (4%) 2 (2%) 6 (6%) 0.43
Allergen specific elimination 62 (44%) 62 (50%) 43 (40%) 0.31
Elemental diet 15 (11%) 20 (16%) 12 (11%) 0.17

Six food elimination included restriction of cow’s milk, hen’s egg, soy, wheat, nuts, fish, and shellfish. Data shown as number (n) and % of specific population. P-value considered significant if < 0.05. EG: eosinophilic gastritis, EGE: eosinophilic gastroenteritis, EC: eosinophilic colitis, EGID: eosinophilic gastrointestinal disorder, PPI: proton-pump inhibitor, 5-ASA: 5-aminosalicyclic acid.